The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ reinfusion in multiple myeloma. Issue 4 (August 2017)

• Record Type: Journal Article
• Authors: Martin, Robert M.G.; Ricci, Michael J.; Foley, Ronan; Mian, Hira S.
• Is Part Of: Transfusion and apheresis science. Volume 56:Issue 4(2017)
• Page Start: 552
• Page End: 557
• Publication Date: 2017-08
• Subjects: Multiple myeloma -- CD34+ stem cell count -- Autologous stem cell transplant; Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2017.06.002
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: Autologous hematopoietic stem cell transplantation (ASCT) is an established treatment for multiple myeloma (MM), yet the impact of transplanted CD34+ cell dose remains unresolved, especially in patients over the age of 65 years. Data was collected from 207 consecutive ASCT patients to determine the relationship between CD34+ infusion count and short-term and long-term platelet recovery. For MM patients under the age of 65 years ( n = 155), CD34+ dosage correlates with time to platelet engraftment ( p < 0.001) and platelet count at 30 days ( p = 0.003), but not with long-term platelet counts at 180 or 360 days from the CD34+ reinfusion. For MM patients aged 65 years or older ( n = 46), CD34+ dosage did not correlate with time to platelet engraftment, but did correlate with both short-term and long-term platelet counts at 30 ( p < 0.001), 180 ( p = 0.021), and 360 days ( p = 0.005). Exploratory regression analysis was done to explore platelet stability following the current minimum CD34+ dosage reinfusion. For MM patients under the age of 65 years, the minimum standard CD34+ dosage of 2 × 10 6 cells/kg was sufficient for a timing to platelet engraftment of <21 days and short-term platelets count ≥150 × 10 9 /L at 30 days. Alternatively, for MM patients aged 65 years or older, the CD34+ dosage of 2 × 10 6 cells/kg was insufficient for platelet counts ≥150 × 10 9 /L at 30 and only marginally attainable at 360 days suggesting that in elderly MM patients a higher CD34+ dosage may be required for platelet recovery and possibly long-term platelet stability.